Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE